AXL endows cancer cells with resistance to treatment through activation of PI3K/AKT pathway and up-regulation of programmed cell death ligand 1 (PD-L1) transcription in head and neck cancer cells, thereby inhibiting the immune killing effect of the body [88]. The gene discussed is AXL; the disease is head and neck cancer.